

FOR OFFICIAL USE ONLY

ACCESS DB # 307584
PLEASE PRINT CLEARLY

RECEIVED

Scientific and Technical Information Center

SEP -3 2009

SEARCH REQUEST FORM

Requester's Full Name: JAMES D. ANDERSON Examiner #: _____ Date: 9/3/09
 Art Unit: 1614 Phone Number: 2-9033 Serial Number: 10/594,412
 Location (Indy/Roanoke): REM 104 (Indy) or REM 3C29 Results Format Preferred (circle): CAPTION LINK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or file out the following:

M9Title of Invention: USE OF 9H-2,6-DIAMINE DERIVATIVESInventors (please provide full name): Baenteli, Rolf; Chene, Patrick; Collingwood, Stephen; Furet, Pascal; Meier, Peter; Schoepfer, JosephEarliest Priority Date: 4/5/2004

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the exact species or structures, laypersons, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or listed parent numbers) along with the appropriate serial number.

① PLEASE SEARCH COMPOUNDS OF THE ATTACHED
FORMULA (I) IN CLAIM 4.

THXNS!

RECEIVED
SEP -3 2009
STN
SEARCHED BY [initials]

JM


INVENTOR SEARCH

=> d ibib abs hitstr 19 1

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:1123774 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:405752
 TITLE: Preparation and use of 9H-purine-2,6-diamine derivatives in the treatment of cancer
 INVENTOR(S): Baenteli, Rolf; Chene, Patrick;
 Collingwood, Stephen Paul; Furet,
 Pascal; Meier, Peter; Schoepfer,
 Joseph
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097135	A2	20051020	WO 2005-EP3521	20050404
WO 2005097135	A3	20060216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005230388	A1	20051020	AU 2005-230388	20050404
CA 2559014	A1	20051020	CA 2005-2559014	20050404
EP 1734968	A2	20061227	EP 2005-751682	20050404
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1946405	A	20070411	CN 2005-80012119	20050404
BR 2005009655	A	20071009	BR 2005-9655	20050404
JP 2007531721	T	20071108	JP 2007-505519	20050404
MX 2006011486	A	20070312	MX 2006-11486	20061004
KR 2007033962	A	20070327	KR 2006-720763	20061004
IN 2006CN03675	A	20070706	IN 2006-CN3675	20061005
US 20070249639	A1	20071025	US 2007-594412	20070530
PRIORITY APPLN. INFO.:			GB 2004-7723	A 20040405
			WO 2005-EP3521	W 20050404
OTHER SOURCE(S):	CASREACT 143:405752; MARPAT 143:405752			
GI				




AB The title compds. I [R2 = aryl, bicyclic aryl, heteroaryl, bicyclic heteroaryl; R6 = aryl, heteroaryl, bicyclic aryl, bicyclic heteroaryl, aliphatic moiety; R8 = H, halo, lower alkyl, lower alkenyl, cycloalkyl, COMe, NR12R13, R12, R13 = H, lower alkyl; R9 = H, lower alkyl; NR6R9 = heterocycle] were prepared. For example, reacting 2-chloro-6-(cycloheptylamo)-9H-purine with 6-aminobenzothiazole gave I [R2 = benzothiazol-6-yl, R6 = cycloheptyl, R8 = R9 = H]. I are useful in treating proliferative diseases dependent on topoisomerase II.

IT 142805-56-9, Topoisomerase II


RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of 9H-purine-2,6-diamine derivs., anticancer activity and

kinase inhibition)
 RN 142805-56-9 HCPLUS
 CN Isomerase, deoxyribonucleate topo-, II (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 IT 867031-80-9P 867031-81-0P 867031-82-1P
 867031-83-2P 867031-84-3P 867031-85-4P
 867031-86-5P 867031-87-6P 867031-88-7P
 867031-89-8P 867031-90-1P 867031-91-2P
 867031-92-3P 867031-93-4P 867031-94-5P
 867031-95-6P 867031-96-7P 867031-98-9P
 867031-99-0P 867032-03-9P 867032-04-0P
 867032-05-1P 867032-07-3P 867032-08-4P,
 [6-[2-(Morpholin-4-yl)ethoxy]naphthalen-2-yl]amine 867032-09-5P
 , [2-[2-(Morpholin-4-yl)ethoxy]benzothiazol-6-yl]amine
 867032-10-6P, 4-[2-[6-Bromonaphthalen-2-yl]oxyethyl]morpholine
 867032-11-9P, 2-Methyl-5-nitro-1H-indole-1-carboxylic acid
 tert-butyl ester 867032-13-1P,
 2-[2-(Morpholin-4-yl)ethoxy]-6-nitrobenzothiazole 867032-15-3P
 867032-18-6P, 9-[Bis(4-methoxyphenyl)methyl]-2,6-dichloro-9H-
 purine 867032-20-0P 867032-25-5P
 867032-28-8P 867032-29-9P 867032-31-3P
 867032-32-4P 867032-33-5P 867032-34-6P
 867032-35-7P 867032-36-8P 867032-37-9P
 867032-38-0P 867032-39-1P 867032-40-4P
 867032-42-6P 867032-43-7P 867032-44-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 9H-purine-2,6-diamine derivs., anticancer activity and
 kinase inhibition)
 RN 867031-80-9 HCPLUS
 CN 9H-Purin-6-amine, 2-chloro-N-cycloheptyl- (CA INDEX NAME)



RN 867031-81-0 HCPLUS
 CN 1-Propanol, 2-[(2-chloro-9H-purin-6-yl)amino]-2-methyl- (CA INDEX NAME)




10/594,412

9/5/09


RN 867031-82-1 HCPLUS

CN 9H-Purin-6-amine, 2-chloro-N-tricyclo[3.3.1.13,7]dec-2-yl- (CA INDEX NAME)




RN 867031-83-2 HCPLUS

CN 9H-Purin-6-amine, 2-chloro-N-cyclooctyl- (CA INDEX NAME)




RN 867031-84-3 HCPLUS

CN Cyclohexanol, 4-[(2-chloro-9H-purin-6-yl)amino]- (CA INDEX NAME)




RN 867031-85-4 HCPLUS


CN 6-Quinolinamine, N-(2-chloro-9H-purin-6-yl)- (CA INDEX NAME)




RN 867031-86-5 HCPLUS
 CN 9H-Purin-6-amine, 2-chloro-N-(diphenylmethyl)- (CA INDEX NAME)




RN 867031-87-6 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(diphenylmethyl)-N2-6-quinolinyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-88-7 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-6-benzothiazolyl-9-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867031-89-8 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-2-naphthalenyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-90-1 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-6-quinoliny1)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-91-2 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-5-benzothiazolyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)



RN 867031-92-3 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-[2-(1,1-dimethylethyl)-6-benzothiazolyl]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-93-4 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-cycloheptyl-N2-6-quinolinyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-94-5 HCPLUS

CN 9H-Purine-2,6-diamine, N2-[4-(2-benzothiazolyl)phenyl]-N6-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-95-6 HCPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(6-methoxy-2-naphthalenyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)



RN 867031-96-7 HCPLUS


CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-[6-[2-(4-morpholinyl)ethoxy]-2-naphthalenyl]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)



RN 867031-98-9 HCPLUS

CN 9H-Purine-2,6-diamine, 9-[bis(4-methoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe


RN 867031-99-0 HCPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-03-9 HCPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-8-cyclopropyl-N6-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-04-0 HCPLUS

CN 9*H*-Purine-2,6,8-triamine, N2-6-benzothiazolyl-N8-[(2,4-dimethoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-9-(tetrahydro-2*H*-pyran-2-yl)- (CA INDEX NAME)




RN 867032-05-1 HCPLUS

CN 9*H*-Purine-2,6,8-triamine, N8-[(2,4-dimethoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-N2-2-naphthalenyl-9-(tetrahydro-2*H*-pyran-2-yl)- (CA INDEX NAME)




RN 867032-07-3 HCPLUS

CN 9*H*-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-(1-ethoxyethenyl)-9-(tetrahydro-2*H*-pyran-2-yl)- (CA INDEX NAME)




RN 867032-08-4 HCPLUS

CN 2-Naphthalenamine, 6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 867032-09-5 HCPLUS

CN 6-Benzothiazolamine, 2-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 867032-10-8 HCPLUS

CN Morpholine, 4-[2-[(6-bromo-2-naphthalenyl)oxy]ethyl]- (CA INDEX NAME)




RN 867032-11-9 HCPLUS

CN 1H-Indole-1-carboxylic acid, 2-methyl-5-nitro-, 1,1-dimethylethyl ester
(CA INDEX NAME)



RN 867032-13-1 HCPLUS


CN Benzothiazole, 2-[2-(4-morpholinyl)ethoxy]-6-nitro- (CA INDEX NAME)



RN 867032-15-3 HCPLUS


CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-

(CA INDEX NAME)




RN 867032-18-6 HCPLUS

CN 9H-Purine, 9-[bis(4-methoxyphenyl)methyl]-2,6-dichloro- (CA INDEX NAME)




RN 867032-20-0 HCPLUS

CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-ethyl- (CA INDEX NAME)




RN 867032-25-5 HCPLUS

CN 9H-Purin-6-amine, 8-bromo-2-chloro-N-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-28-8 HCPLUS


CN 9H-Purine, 8-bromo-2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-29-9 HCPLUS
 CN 9H-Purine, 2,6-dichloro-8-(1-ethoxyethenyl)-9-(tetrahydro-2H-pyran-2-yl)-
 (CA INDEX NAME)




RN 867032-31-3 HCPLUS
 CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-methyl- (CA INDEX NAME)




RN 867032-32-4 HCPLUS
 CN 9H-Purin-6-amine, 2-chloro-N-cycloheptyl-8-methyl- (CA INDEX NAME)




RN 867032-33-5 HCPLUS
 CN 9H-Purin-6-amine, 2-chloro-8-ethyl-N-(2,2,2-trifluoro-1-methylethyl)- (CA INDEX NAME)




RN 867032-34-6 HCAPLUS
 CN 9H-Purine, 2-chloro-8-ethyl-6-(2-methyl-1-pyrrolidinyl)- (CA INDEX NAME)




RN 867032-35-7 HCAPLUS
 CN Butanamide, 3-[(2-chloro-8-ethyl-9H-purin-6-yl)amino]- (CA INDEX NAME)




RN 867032-36-8 HCAPLUS
 CN Butanoic acid, 3-[(2-chloro-8-ethyl-9H-purin-6-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 867032-37-9 HCAPLUS
 CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-propyl- (CA INDEX NAME)




RN 867032-38-0 HCAPLUS
 CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-(1-methylethyl)- (CA INDEX NAME)




RN 867032-39-1 HCAPLUS
 CN 9H-Purin-6-amine, 2-chloro-8-cyclopentyl-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 867032-40-4 HCAPLUS
 CN 9H-Purin-6-amine, 2-chloro-8-cyclopropyl-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-42-6 HCAPLUS
 CN Ethanimidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, ethyl ester (CA INDEX NAME)




RN 867032-43-7 HCAPLUS
 CN Propanimidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, ethyl ester

(CA INDEX NAME)




RN 867032-44-8 HCAPLUS
 CN Butanimidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, methyl ester
 (CA INDEX NAME)




IT	325166-80-1P	867032-49-3P	867032-50-6P
	867032-51-7P	867032-52-8P	867032-53-9P
	867032-54-0P	867032-55-1P	867032-56-2P
	867032-57-3P	867032-58-4P	867032-59-5P
	867032-60-8P	867032-61-9P	867032-62-0P
	867032-63-1P	867032-64-2P	867032-65-3P
	867032-66-4P	867032-67-5P	867032-68-6P
	867032-69-7P	867032-70-0P	867032-71-1P
	867032-72-2P	867032-73-3P	867032-74-4P
	867032-75-5P	867032-76-6P	867032-77-7P
	867032-78-8P	867032-79-9P	867032-80-2P
	867032-81-3P	867032-82-4P	867032-83-5P
	867032-84-6P	867032-85-7P	867032-86-8P
	867032-87-9P	867032-88-0P	867032-89-1P
	867032-90-4P	867032-91-5P	867032-92-6P
	867032-93-7P	867032-94-8P	867032-95-9P
	867032-96-0P	867032-97-1P	867032-98-2P
	867032-99-3P	867033-00-9P	867033-01-0P
	867033-02-1P	867033-03-2P	867033-04-3P
	867033-05-4P	867033-06-5P	867033-07-6P
	867033-08-7P	867033-09-8P	867033-10-1P
	867033-11-2P	867033-12-3P	867033-13-4P
	867033-14-5P	867033-15-6P	867033-16-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of 9H-purine-2,6-diamine derivs., anticancer activity and kinase inhibition)


RN 325166-80-1 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-49-3 HCPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-cycloheptyl- (CA INDEX NAME)




RN 867032-50-6 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-cycloheptyl-N2-[4-(2-thiazolyl)phenyl]- (CA INDEX NAME)




RN 867032-51-7 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-cycloheptyl-N2-6-quinolinyl- (CA INDEX NAME)




RN 867032-52-8 HCPLUS
 CN 1-Propanol, 2-[(2-(6-benzothiazolylamino)-9H-purin-6-yl)amino]-2-methyl- (CA INDEX NAME)




RN 867032-53-9 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-tricyclo[3.3.1.13,7]dec-2-yl-
 (CA INDEX NAME)



RN 867032-54-0 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-bicyclo[2.2.1]hept-2-yl-
 (CA INDEX NAME)




RN 867032-55-1 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-cyclooctyl- (CA INDEX NAME)




RN 867032-56-2 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(3-methoxyphenyl)- (CA


(CA INDEX NAME)




RN 867032-57-3 HCPLUS
 CN Cyclohexanol, 4-[(2-(6-benzothiazolylamino)-9H-purin-6-yl)amino]- (CA INDEX NAME)




RN 867032-58-4 HCPLUS
 CN 9H-Purine-2,6-diamine, N2,N6-di-6-quinolinyl- (CA INDEX NAME)




RN 867032-59-5 HCPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(diphenylmethyl)- (CA INDEX NAME)




RN 867032-60-8 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-phenyl-N2-6-quinolinyl- (CA INDEX NAME)




RN 867032-61-9 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(diphenylmethyl)-N2-6-quinolinyl- (CA INDEX NAME)




RN 867032-62-0 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867032-63-1 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-6-quinolinyl)- (CA INDEX NAME)




RN 867032-64-2 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-5-benzothiazolyl)- (CA INDEX NAME)




RN 867032-65-3 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-[2-(1,1-dimethylethyl)-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-66-4 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-6-benzothiazolyl)- (CA INDEX NAME)




RN 867032-67-5 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-[4-(2-benzothiazolyl)phenyl]-N6-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-68-6 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(6-methoxy-2-naphthalenyl)- (CA INDEX NAME)




RN 867032-69-7 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-[6-[2-(4-morpholinyl)ethoxy]-2-naphthalenyl]- (CA INDEX NAME)




RN 867032-70-0 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-1H-indol-5-yl)-
 (CA INDEX NAME)




RN 867032-71-1 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-1H-indol-5-yl- (CA INDEX
 NAME)




RN 867032-72-2 HCPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-methyl-
 (CA INDEX NAME)




RN 867032-73-3 HCPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-cycloheptyl-8-methyl- (CA
 INDEX NAME)




RN 867032-74-4 HCPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-ethyl-
 (CA INDEX NAME)




RN 867032-75-5 HCPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-8-ethyl-N6-(2,2,2-trifluoro-1-methylethyl)- (CA INDEX NAME)




RN 867032-76-6 HCPLUS
 CN 9H-Purin-2-amine, N6-benzothiazolyl-8-ethyl-6-(2-methyl-1-pyrrolidinyl)-
 (CA INDEX NAME)




RN 867032-77-7 HCPLUS
 CN Butanamide, 3-[2-(6-benzothiazolylamino)-8-ethyl-9H-purin-6-yl]amino-
 (CA INDEX NAME)




RN 867032-78-8 HCPLUS
 CN Butanoic acid, 3-[2-(6-benzothiazolylamino)-8-ethyl-9H-purin-6-yl]amino-, ethyl ester (CA INDEX NAME)




RN 867032-79-9 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-propyl-
 (CA INDEX NAME)




RN 867032-80-2 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-(1-methylethyl)- (CA INDEX NAME)




RN 867032-81-3 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-8-cyclopentyl-N6-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-82-4 HCAPLUS
 CN 2H-1-Benzopyran-2-one, 6-[{6-[(1,1-dimethylethyl)amino]-8-ethyl-9H-purin-2-yl}amino]- (CA INDEX NAME)




RN 867032-83-5 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-(methylthio)-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-84-6 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-85-7 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(1-methylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-86-8 HCAPLUS
 CN 9H-Purine-2,6-diamine, 8-cyclopropyl-N6-(1,1-dimethylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-87-9 HCAPLUS
 CN 9H-Purine-2,6-diamine, 8-cyclopentyl-N6-(1,1-dimethylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-88-0 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-8-cyclopropyl-N6-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-89-1 HCAPLUS
 CN 9H-Purine-2,6,8-triamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-90-4 HCAPLUS
 CN 9H-Purine-2,6,8-triamine, N6-(1,1-dimethylethyl)-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867032-91-5 HCAPLUS
 CN 9H-Purine-2,6,8-triamine, N6-(1,1-dimethylethyl)-N8-methyl-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867032-92-6 HCAPLUS
 CN Ethanone, 1-[2-(6-benzothiazolylamino)-6-[(1,1-dimethylethyl)amino]-9H-purin-8-yl]- (CA INDEX NAME)




RN 867032-93-7 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-6-quinolinyl- (CA INDEX NAME)




RN 867032-94-8 HCPLUS
 CN 9H-Purine-2,6-diamine, N2-2,1,3-benzothiadiazol-5-yl-N6-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-95-9 HCPLUS
 CN 9H-Purine-2,6-diamine, N2-2,1,3-benzothiadiazol-5-yl-N6-cycloheptyl- (CA INDEX NAME)




RN 867032-96-0 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-cycloheptyl-N2-(2-methyl-6-benzothiazolyl)- (CA INDEX NAME)




RN 867032-97-1 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylpropyl)- (CA INDEX NAME)




RN 867032-98-2 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylpropyl)-N2-6-quinolinyl- (CA INDEX NAME)



RN 867032-99-3 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-1,3-benzothiadiazol-5-yl-N6-(1,1-dimethylpropyl)- (CA INDEX NAME)




RN 867033-00-9 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylpropyl)-N2-(2-methyl-6-benzothiazolyl)- (CA INDEX NAME)




RN 867033-01-0 HCPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-[2-(4-fluorophenyl)-1,1-dimethylethyl]- (CA INDEX NAME)




RN 867033-02-1 HCPLUS

CN 9H-Purine-2,6-diamine, N6-[2-(4-fluorophenyl)-1,1-dimethylethyl]-N2-6-quinolinyl- (CA INDEX NAME)




RN 867033-03-2 HCPLUS

CN 9H-Purine-2,6-diamine, N2-2,1,3-benzothiadiazol-5-yl-N6-[2-(4-fluorophenyl)-1,1-dimethylethyl]- (CA INDEX NAME)




RN 867033-04-3 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-[2-(4-fluorophenyl)-1,1-dimethylethyl]-N2-(2-methyl-6-benzothiazolyl)- (CA INDEX NAME)




RN 867033-05-4 HCAPLUS

CN 9H-Purin-2-amine, N6-benzothiazolyl-6-[4-(3-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 867033-06-5 HCAPLUS


CN 9H-Purin-2-amine, N6-benzothiazolyl-6-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 867033-07-6 HCPLUS
CN 6-Quinolinamine, N-[6-[4-(2-pyridinyl)-1-piperazinyl]-9H-purin-2-yl]- (CA INDEX NAME)




RN 867033-08-7 HCAPLUS
CN 9H-Purin-2-amine, N-2,1,3-benzothiadiazol-5-yl-6-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 867033-09-8 HCAPLUS
CN 9H-Purin-2-amine, N-(2-methyl-6-benzothiazolyl)-6-[4-(2-pyridinyl)-1-piperazinyl- (CA INDEX NAME)




RN 867033-10-1 HCPLUS
 CN 6-Quinolinamine, N-[6-{4-(2-pyrazinyl)-1-piperazinyl}-9H-purin-2-yl]- (CA INDEX NAME)




RN 867033-11-2 HCPLUS
 CN 9H-Purine-2,6-diamine, 8-bromo-N6-(1,1-dimethylethyl)-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867033-12-3 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethenyl-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867033-13-4 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-2-naphthalenyl-8-(2-propen-1-yl)- (CA INDEX NAME)




RN 867033-14-5 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-methyl-N2-2-naphthalenyl-
 (CA INDEX NAME)



RN 867033-15-6 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-2-naphthalenyl-
 (CA INDEX NAME)



RN 867033-16-7 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(2-methylpropyl)-N2-2-naphthalenyl-
 (CA INDEX NAME)



IT 867032-12-0P, 5-Amino-2-methylindole-1-carboxylic acid
 tert-butyl ester 867032-14-2P 867032-16-4P

867032-17-5P 867032-19-7P 867032-21-1P

867032-22-2P 867032-23-3P 867032-24-4P

867032-26-6P 867032-27-7P 867032-30-2P

867033-17-8P 867033-18-9P 867033-19-0P

867033-20-3P 867033-21-4P 867033-22-5P


867033-23-6P 867033-24-7P 867033-25-8P

867033-27-0P 867033-28-1P 867033-29-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 9H-purine-2,6-diamine derivs., anticancer activity and kinase inhibition)


RN 867032-12-0 HCPLUS

CN 1H-Indole-1-carboxylic acid, 5-amino-2-methyl-, 1,1-dimethylethyl ester
(CA INDEX NAME)


RN 867032-14-2 HCPLUS

CN 9H-Purin-6-amine, 2-chloro-N-(diphenylmethyl)-9-(tetrahydro-2H-pyran-2-yl)-
(CA INDEX NAME)

RN 867032-16-4 HCPLUS


CN 9H-Purin-6-amine, 2-chloro-N-cycloheptyl-9-(tetrahydro-2H-pyran-2-yl)-
(CA INDEX NAME)

RN 867032-17-5 HCPLUS

CN 9H-Purin-6-amine, 2-chloro-8-cyclopropyl-N-(1,1-dimethylethyl)-9-
(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)


RN 867032-19-7 HCPLUS

CN 9H-Purin-6-amine, 9-[bis(4-methoxyphenyl)methyl]-2-chloro-N-(1,1-
dimethylethyl)- (CA INDEX NAME)




RN 867032-21-1 HCPLUS

CN 9H-Purin-6-amine, 9-[bis(4-methoxyphenyl)methyl]-2-chloro-N-(1,1-dimethylethyl)-8-ethyl- (CA INDEX NAME)




RN 867032-22-2 HCPLUS

CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-ethyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-23-3 HCPLUS

CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-(1-methylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-24-4 HCPLUS


CN 9H-Purin-6-amine, 2-chloro-8-cyclopentyl-N-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-26-6 HCPLUS
 CN 9H-Purine-6,8-diamine, 2-chloro-N8-[(2,4-dimethoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-27-7 HCPLUS
 CN 9H-Purine-6,8-diamine, 2-chloro-N8-[(2,4-dimethoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-N8-methyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-30-2 HCPLUS
 CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-(1-ethoxyethenyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867033-17-8 HCPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-cycloheptyl-8-ethyl- (CA INDEX NAME)




RN 867033-18-9 HCPLUS
CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(1-methylethyl)-N2-[3-[5-methyl-2-[2-(4-morpholinyl)ethoxy]-4-thiazolyl]-2-propen-1-ylidene]-(CA INDEX NAME)




RN 867033-19-0 HCPLUS
CN 9H-Purine-2,6-diamine, 8-cyclopropyl-N6-(1,1-dimethylethyl)-N2-[3-[5-methyl-2-[2-(4-morpholinyl)ethoxy]-4-thiazolyl]-2-propen-1-ylidene]-(CA INDEX NAME)




RN 867033-20-3 HCPLUS
CN 9H-Purine-2,6-diamine, 8-cyclopentyl-N6-(1,1-dimethylethyl)-N2-[3-[5-methyl-2-[2-(4-morpholinyl)ethoxy]-4-thiazolyl]-2-propen-1-ylidene]-(CA INDEX NAME)




RN 867033-21-4 HCPLUS
CN 1H-Indole-1-carboxylic acid, 5-[(9-[bis(4-methoxyphenyl)methyl]-6-[(1,1-dimethylethyl)amino]-9H-purin-2-yl]amino]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 867033-22-5 HCPLUS
 CN 9H-Purine-2,6-diamine, 9-[bis(4-methoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-N2-1H-indol-5-yl- (CA INDEX NAME)



RN 867033-23-6 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(1-methylethyl)-N2-[3-[5-methyl-2-[2-(4-morpholinyl)ethoxy]-4-thiazolyl]-2-propen-1-ylidene]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867033-24-7 HCPLUS
 CN 9H-Purine-2,6-diamine, 8-cyclopropyl-N6-(1,1-dimethylethyl)-N2-[3-[5-methyl-2-[2-(4-morpholinyl)ethoxy]-4-thiazolyl]-2-propen-1-ylidene]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867033-25-8 HCAPLUS

CN 9H-Purine-2,6-diamine, 8-cyclopentyl-N6-(1,1-dimethylethyl)-N2-[3-{5-methyl-2-[2-(4-morpholinyl)ethoxy]-4-thiazolyl}-2-propen-1-ylidene]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867033-27-0 HCAPLUS

CN Propanimidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-2-methyl-, ethyl ester (CA INDEX NAME)




RN 867033-28-1 HCAPLUS

CN Cyclopentanecarboximidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, ethyl ester (CA INDEX NAME)



RN 867033-29-2 HCAPLUS

CN Cyclopropanecarboximidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, ethyl ester (CA INDEX NAME)




IT 75-64-9, tert-Butylamine, reactions 78-39-7
 91-00-9 91-59-8, 2-Naphthalenamine 110-87-2
 , 3,4-Dihydro-2H-pyran 115-80-0 124-68-5
 533-30-2, 6-Aminobenzothiazole 536-90-3

580-15-4, 6-Quinolinamine 594-39-8 597-64-8
 622-40-2, 2-(Morpholin-4-yl)ethanol 728-87-0,
 Bis(4-methoxyphenyl)methanol 765-38-8 822-98-0,
 Bicyclo[2.2.1]heptan-2-amine 874-37-3,
 2,1,3-Benzothiadiazol-5-amine 1089-59-4 1200-27-7
 2407-11-6, 2-Chloro-6-nitrobenzothiazole 2941-62-0
 3240-94-6, 4-(2-Chloroethyl)morpholine 3531-43-9
 5111-65-9, 2-Bromo-6-methoxynaphthalene 5303-65-1
 5451-40-1, 2,6-Dichloro-9H-purine 5452-35-7,
 Cycloheptylamine 5452-37-9, Cyclooctanamine
 5959-32-0 6278-73-5, 4-(2-Benzothiazolyl)benzenamine
 6850-65-3 7486-35-3 7570-47-0,
 2-Methyl-5-nitro-1H-indole 13074-39-0, 2-Adamantanamine
 13332-43-9, 2-Methylbenzothiazol-5-amine 14415-44-2
 15231-91-1, 6-Bromonaphthalen-2-ol 20419-68-5,
 2,6-Dichloro-9-(tetrahydropyran-2-yl)-9H-purine 20781-20-8,
 (2,4-Dimethoxybenzyl)amine 24850-33-7 25706-29-0
 34803-68-4 41796-01-4 43083-12-1
 58460-11-0, 2-(tert-Butyl)benzothiazol-6-amine
 65079-19-8, 2-Methyl-6-quinolinamine 67980-77-2
 97674-02-7, Tributyl(1-ethoxyvinyl)stannane 102503-23-1
 , (2,4-Dimethoxybenzyl)methylamine 130838-36-7
 166104-20-7, 1-(tert-Butoxycarbonyl)indol-5-amine
 185408-97-3 190654-89-8 193017-26-4
 411235-57-9, Cyclopropylboronic acid 736100-88-2
 746556-17-2 867032-48-2 1042953-23-0
 1042953-41-2 1042953-86-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 9H-purine-2,6-diamine derivs., anticancer activity and
 kinase inhibition)

RN 75-64-9 HCPLUS

CN 2-Propanamine, 2-methyl- (CA INDEX NAME)



RN 78-39-7 HCPLUS

CN Ethane, 1,1,1-triethoxy- (CA INDEX NAME)




RN 91-00-9 HCPLUS

CN Benzenemethanamine, α -phenyl- (CA INDEX NAME)



RN 91-59-8 HCAPLUS
 CN 2-Naphthalenamine (CA INDEX NAME)




RN 110-87-2 HCAPLUS
 CN 2H-Pyran, 3,4-dihydro- (CA INDEX NAME)




RN 115-80-0 HCAPLUS
 CN Propane, 1,1,1-triethoxy- (CA INDEX NAME)




RN 124-68-5 HCAPLUS
 CN 1-Propanol, 2-amino-2-methyl- (CA INDEX NAME)




RN 533-30-2 HCAPLUS
 CN 6-Benzothiazolamine (CA INDEX NAME)



RN 536-90-3 HCAPLUS
 CN Benzenamine, 3-methoxy- (CA INDEX NAME)



RN 580-15-4 HCAPLUS
 CN 6-Quinolinamine (CA INDEX NAME)




RN 594-39-8 HCAPLUS
 CN 2-Butanamine, 2-methyl- (CA INDEX NAME)




RN 597-64-8 HCAPLUS
 CN Stannane, tetraethyl- (CA INDEX NAME)



RN 622-40-2 HCAPLUS
 CN 4-Morpholineethanol (CA INDEX NAME)



RN 728-87-0 HCAPLUS
 CN Benzenemethanol, 4-methoxy- α -(4-methoxyphenyl)- (CA INDEX NAME)




RN 765-38-8 HCAPLUS
 CN Pyrrolidine, 2-methyl- (CA INDEX NAME)



RN 822-98-0 HCAPLUS
 CN Bicyclo[2.2.1]heptan-2-amine (CA INDEX NAME)




RN 874-37-3 HCAPLUS
 CN 2,1,3-Benzothiadiazol-5-amine (CA INDEX NAME)




RN 1089-59-4 HCAPLUS
 CN Stannane, methyltriphenyl- (CA INDEX NAME)




RN 1200-27-7 HCAPLUS
 CN Benzeneethanamine, 4-fluoro- α,α -dimethyl- (CA INDEX NAME)




RN 2407-11-6 HCAPLUS
 CN Benzothiazole, 2-chloro-6-nitro- (CA INDEX NAME)




RN 2941-62-0 HCAPLUS
 CN 6-Benzothiazolamine, 2-methyl- (CA INDEX NAME)




RN 3240-94-6 HCAPLUS
 CN Morpholine, 4-(2-chloroethyl)- (CA INDEX NAME)




RN 3531-43-9 HCAPLUS
 CN Stannane, tetrakis(2-methylpropyl)- (CA INDEX NAME)



RN 5111-65-9 HCAPLUS
 CN Naphthalene, 2-bromo-6-methoxy- (CA INDEX NAME)



RN 5303-65-1 HCAPLUS
 CN Butanoic acid, 3-amino-, ethyl ester (CA INDEX NAME)




RN 5451-40-1 HCAPLUS


10/594,412

9/5/09


CN 9H-Purine, 2,6-dichloro- (CA INDEX NAME)



RN 5452-35-7 HCAPLUS
CN Cycloheptanamine (CA INDEX NAME)




RN 5452-37-9 HCAPLUS
CN Cyclooctanamine (CA INDEX NAME)




RN 5959-32-0 HCAPLUS
CN Butanamide, 3-amino- (CA INDEX NAME)



RN 6278-73-5 HCAPLUS
CN Benzenamine, 4-(2-benzothiazolyl)- (CA INDEX NAME)




RN 6850-65-3 HCAPLUS
CN Cyclohexanol, 4-amino- (CA INDEX NAME)



RN 7486-35-3 HCAPLUS
 CN Stannane, tributylethenyl- (CA INDEX NAME)




RN 7570-47-0 HCAPLUS
 CN 1H-Indole, 2-methyl-5-nitro- (CA INDEX NAME)




RN 13074-39-0 HCAPLUS
 CN Tricyclo[3.3.1.13,7]decan-2-amine (CA INDEX NAME)




RN 13382-43-9 HCAPLUS
 CN 5-Benzothiazolamine, 2-methyl- (CA INDEX NAME)




RN 14415-44-2 HCAPLUS
 CN 2H-1-Benzopyran-2-one, 6-amino- (CA INDEX NAME)




RN 15231-91-1 HCAPLUS
 CN 2-Naphthalenol, 6-bromo- (CA INDEX NAME)




RN 20419-68-5 HCAPLUS
 CN 9H-Purine, 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 20781-20-8 HCAPLUS
 CN Benzenemethanamine, 2,4-dimethoxy- (CA INDEX NAME)




RN 24850-33-7 HCAPLUS
 CN Stannane, tributyl-2-propen-1-yl- (CA INDEX NAME)



RN 25706-29-0 HCAPLUS
 CN 6-Benzothiazolamine, 2-(methylthio)- (CA INDEX NAME)




RN 34803-68-4 HCAPLUS
 CN Pyrazine, 2-(1-piperazinyl)- (CA INDEX NAME)




RN 41796-01-4 HCAPLUS
 CN Propanimidic acid, 2-methyl-, methyl ester (CA INDEX NAME)




RN 43083-12-1 HCPLUS
 CN Butane, 1,1,1-trimethoxy- (CA INDEX NAME)




RN 58460-11-0 HCPLUS
 CN 6-Benzothiazolamine, 2-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 65079-19-8 HCPLUS
 CN 6-Quinolinamine, 2-methyl- (CA INDEX NAME)




RN 67980-77-2 HCPLUS
 CN Piperazine, 1-(3-pyridinyl)- (CA INDEX NAME)




RN 97674-02-7 HCPLUS
 CN Stannane, tributyl(1-ethoxyethenyl)- (CA INDEX NAME)




RN 102503-23-1 HCPLUS
 CN Benzenemethanamine, 2,4-dimethoxy-N-methyl- (CA INDEX NAME)




RN 130838-36-7 HCAPLUS
 CN 4,5-Pyrimidinediamine, 2,6-dichloro- (CA INDEX NAME)




RN 166104-20-7 HCAPLUS
 CN 1H-Indole-1-carboxylic acid, 5-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 185408-97-3 HCAPLUS
 CN 9H-Purin-6-amine, 2-chloro-N-phenyl- (CA INDEX NAME)



RN 190654-89-8 HCAPLUS
 CN 9H-Purin-6-amine, 2-chloro-N-(3-methoxyphenyl)- (CA INDEX NAME)




RN 193017-26-4 HCPLUS
 CN Benzenamine, 4-(2-thiazolyl)- (CA INDEX NAME)




RN 411235-57-9 HCPLUS
 CN Boronic acid, B-cyclopropyl- (CA INDEX NAME)




RN 736100-88-2 HCPLUS
 CN Cyclopentanecarboximidic acid, methyl ester (CA INDEX NAME)



RN 746556-17-2 HCPLUS
 CN Cyclopropanecarboximidic acid, methyl ester (CA INDEX NAME)




RN 867032-48-2 HCPLUS
 CN 9H-Purin-6-amine, N-bicyclo[2.2.1]hept-2-yl-2-chloro- (CA INDEX NAME)




RN 1042953-23-0 HCPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-6-benzothiazolyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 1042953-41-2 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 5-[(6-[(1,1-dimethylethyl)amino]-1-(tetrahydro-2H-pyran-2-yl)-1H-purin-2-yl]amino]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1042953-86-5 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 5-[(6-[(1,1-dimethylethyl)amino]-1-(tetrahydro-2H-pyran-2-yl)-1H-purin-2-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 13101-88-7P, 6-Methoxy-2-naphthalenamine 867031-97-8P

867032-00-6P 867032-01-7P 867032-02-8P

867032-45-9P 867032-46-0P 867032-47-1P


867033-26-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 9H-purine-2,6-diamine derivs., anticancer activity and kinase inhibition)


RN 13101-88-7 HCAPLUS

CN 2-Naphthalenamine, 6-methoxy- (CA INDEX NAME)




RN 867031-97-8 HCPLUS

CN 1H-Indole-1-carboxylic acid, 5-[(9-[bis(4-methoxyphenyl)methyl]-6-[(1,1-dimethylethyl)amino]-9H-purin-2-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 867032-00-6 HCPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(1-methylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]-9-(tetrahydro-2H-pyran-2-yl)-(CA INDEX NAME)




RN 867032-01-7 HCPLUS

CN 9H-Purine-2,6-diamine, 8-cyclopropyl-N6-(1,1-dimethylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]-9-(tetrahydro-2H-pyran-2-yl)-(CA INDEX NAME)




RN 867032-02-8 HCPLUS

CN 9H-Purine-2,6-diamine, 8-cyclopentyl-N6-(1,1-dimethylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]-9-(tetrahydro-2H-pyran-2-yl)-(CA INDEX NAME)




RN 867032-45-9 HCPLUS

CN Propanimidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-2-methyl-, methyl ester (CA INDEX NAME)




RN 867032-46-0 HCPLUS

CN Cyclopentanecarboximidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, methyl ester (CA INDEX NAME)




RN 867032-47-1 HCPLUS

CN Cyclopropanecarboximidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, methyl ester (CA INDEX NAME)



RN 867033-26-9 HCPLUS


CN 9H-Purine-2,6,8-triamine, N8-[(2,4-dimethoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-N8-methyl-N2-2-naphthalenyl-9-(tetrahydro-2H-pyran-2-yl)-(CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RESULTS FROM SEARCHES IN REGISTRY AND CAPLUS

=> d que stat 113
 L10 STR



VAR G1=H/AK
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
 L12 20 SEA FILE=REGISTRY SSS FUL L10
 L13 1 SEA FILE=HCAPLUS ABB=ON L12

=> d ibib abs hitstr 113 1


L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:1123774 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:405752
 TITLE: Preparation and use of 9H-purine-2,6-diamine derivatives in the treatment of cancer
 INVENTOR(S): Baenteli, Rolf; Chene, Patrick; Collingwood, Stephen Paul; Furet, Pascal; Meier, Peter; Schoepfer, Joseph Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 PATENT ASSIGNEE(S):
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097135	A2	20051020	WO 2005-EP3521	20050404
WO 2005097135	A3	20060216		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005230388	A1	20051020	AU 2005-230388	20050404
CA 2559014	A1	20051020	CA 2005-2559014	20050404
EP 1734968	A2	20061227	EP 2005-751682	20050404
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1946405	A	20070411	CN 2005-80012119	20050404
BR 2005009655	A	20071009	BR 2005-9655	20050404
JP 2007531721	T	20071108	JP 2007-505519	20050404
MX 2006011486	A	20070312	MX 2006-11486	20061004
KR 2007033962	A	20070327	KR 2006-720763	20061004
IN 2006CN03675	A	20070706	IN 2006-CN3675	20061005
US 20070249639	A1	20071025	US 2007-594412	20070530
PRIORITY APPLN. INFO.:			GB 2004-7723	A 20040405
			WO 2005-EP3521	W 20050404

OTHER SOURCE(S): CASREACT 143:405752; MARPAT 143:405752
GI




AB The title compds. I [R2 = aryl, bicyclic aryl, heteroaryl, bicyclic heteroaryl; R6 = aryl, heteroaryl, bicyclic aryl, bicyclic heteroaryl, aliphatic moiety; R8 = H, halo, lower alkyl, lower alkenyl, cycloalkyl, COMe, NR12R13, R12, R13 = H, lower alkyl; R9 = H, lower alkyl; NR6R9 = heterocycle] were prepared For example, reacting 2-chloro-6-(cycloheptylamo)-9H-purine with 6-aminobenzothiazole gave I [R2 = benzothiazol-6-yl, R6 = cycloheptyl, R8 = R9 = H]. I are useful in treating proliferative diseases dependent on topoisomerase II.


IT 867032-72-2P	867032-74-4P	867032-75-5P
867032-77-7P	867032-78-8P	867032-79-9P
867032-80-2P	867032-82-4P	867032-83-5P
867032-84-6P	867032-85-7P	867032-92-6P
867033-12-3P	867033-13-4P	867033-14-5P
867033-15-6P	867033-16-7P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 9H-purine-2,6-diamine derivs., anticancer activity and kinase inhibition)


RN 867032-72-2 HCPLUS
CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-methyl-
(CA INDEX NAME)




RN 867032-74-4 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-ethyl-
 (CA INDEX NAME)




RN 867032-75-5 HCAPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-8-ethyl-N6-(2,2,2-trifluoro-1-
 methylethyl)- (CA INDEX NAME)




RN 867032-77-7 HCAPLUS
 CN Butanamide, 3-[(2-(6-benzothiazolylamino)-8-ethyl-9H-purin-6-yl)amino]-
 (CA INDEX NAME)




RN 867032-78-8 HCAPLUS
 CN Butanoic acid, 3-[(2-(6-benzothiazolylamino)-8-ethyl-9H-purin-6-yl)amino]-,
 ethyl ester (CA INDEX NAME)




RN 867032-79-9 HCPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-propyl-
 (CA INDEX NAME)




RN 867032-80-2 HCPLUS
 CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-(1-methylethyl)- (CA INDEX NAME)



RN 867032-82-4 HCPLUS
 CN 2H-1-Benzopyran-2-one, 6-[(6-[(1,1-dimethylethyl)amino]-8-ethyl-9H-purin-2-yl)amino]- (CA INDEX NAME)




RN 867032-83-5 HCPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-(methylthio)-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-84-6 HCPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-85-7 HCPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(1-methylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-92-6 HCPLUS

CN Ethanone, 1-[2-(6-benzothiazolylamino)-6-[(1,1-dimethylethyl)amino]-9H-purin-8-yl]- (CA INDEX NAME)




RN 867033-12-3 HCPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethenyl-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867033-13-4 HCPLUS


CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-2-naphthalenyl-8-(2-propen-1-yl)- (CA INDEX NAME)




RN 867033-14-5 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-methyl-N2-2-naphthalenyl-
 (CA INDEX NAME)



RN 867033-15-6 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-2-naphthalenyl-
 (CA INDEX NAME)



RN 867033-16-7 HCAPLUS
 CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(2-methylpropyl)-N2-2-naphthalenyl-
 (CA INDEX NAME)



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	11	THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

SEARCH HISTORY

=> d his ful

(FILE 'HOME' ENTERED AT 13:34:32 ON 05 SEP 2009)

FILE 'HCAPLUS' ENTERED AT 13:35:09 ON 05 SEP 2009

	E BAENTELI ROLF/AU
L1	11 SEA ABB=ON ("BAENTELI R"/AU OR "BAENTELI ROLF"/AU)
	E CHENE PATRICK/AU
L2	70 SEA ABB=ON ("CHENE P"/AU OR "CHENE PATRICK"/AU)
	E COLLINGWOOD STEPHEN PAUL/AU
L3	45 SEA ABB=ON ("COLLINGWOOD STEPHEN P"/AU OR "COLLINGWOOD STEPHEN PAUL"/AU)
	E FURET PASCAL/AU
L4	179 SEA ABB=ON ("FURET P"/AU OR "FURET PASCAL"/AU)
	E MEIER PETER/AU
L5	63 SEA ABB=ON "MEIER PETER"/AU
	E SCHOEPFER JOSEPH/AU
L6	49 SEA ABB=ON ("SCHOEPFER JOSEPH"/AU OR "SCHOEPFER JOSEPH G"/AU)
L7	1 SEA ABB=ON L1 AND L2 AND L3 AND L4 AND L5 AND L6 SELECT RN L7 1

FILE 'REGISTRY' ENTERED AT 13:36:31 ON 05 SEP 2009

L8	211 SEA ABB=ON (102503-23-1/B1 OR 1042953-23-0/B1 OR 1042953-41-2/B1 OR 1042953-86-5/B1 OR 1089-59-4/B1 OR 110-87-2/B1 OR 115-80-0/B1 OR 1200-27-7/B1 OR 124-68-5/B1 OR 13074-39-0/B1 OR 130838-36-7/B1 OR 13101-88-7/B1 OR 13382-43-9/B1 OR 142805-56-9/B1 OR 14415-44-2/B1 OR 15231-91-1/B1 OR 166104-20-7/B1 OR 185408-97-3/B1 OR 190654-89-8/B1 OR 193017-26-4/B1 OR 20419-68-5/B1 OR 20781-20-8/B1 OR 2407-11-6/B1 OR 24850-33-7/B1 OR 25706-29-0/B1 OR 2941-62-0/B1 OR 3240-94-6/B1 OR 325166-80-1/B1 OR 34803-68-4/B1 OR 3531-43-9/B1 OR 411235-57-9/B1 OR 41796-01-4/B1 OR 43083-12-1/B1 OR 5111-65-9/B1 OR 5303-65-1/B1 OR 533-30-2/B1 OR 536-90-3/B1 OR 5451-40-1/B1 OR 5452-35-7/B1 OR 5452-37-9/B1 OR 580-15-4/B1 OR 58460-11-0/B1 OR 594-39-8/B1 OR 5959-32-0/B1 OR 597-64-8/B1 OR 622-40-2/B1 OR 6278-73-5/B1 OR 65079-19-8/B1 OR 67980-77-2/B1 OR 6850-65-3/B1 OR 728-87-0/B1 OR 736100-88-2/B1 OR 746556-17-2/B1 OR 7486-35-3/B1 OR 75-64-9/B1 OR 7570-47-0/B1 OR 765-38-8/B1 OR 78-39-7/B1 OR 822-98-0/B1 OR 867031-80-9/B1 OR 867031-81-0/B1 OR 867031-82-1/B1 OR 867031-83-2/B1 OR 867031-84-3/B1 OR 867031-85-4/B1 OR 867031-86-5/B1 OR 867031-87-6/B1 OR 867031-88-7/B1 OR 867031-89-8/B1 OR 867031-90-1/B1 OR 867031-91-2/B1 OR 867031-92-3/B1 OR 867031-93-4/B1 OR 867031-94-5/B1 OR 867031-95-6/B1 OR 867031-96-7/B1 OR 867031-97-8/B1 OR 867031-98-9/B1 OR 867031-99-0/B1 OR 867032-00-6/B1 OR 867032-01-7/B1 OR 867032-02-8/B1 OR 867032-03-9/B1 OR 867032-04-0/B1 OR 867032-05-1/B1 OR 867032-07-3/B1 OR 867032-08-4/B1 OR 867032-09-5/B1 OR 867032-10-8/B1 OR 867032-11-9/B1 OR 867032-12-0/B1 OR 867032-13-1/B1 OR 867032-14-2/B1 OR 867032-15-3/B1 OR 867032-16-4/B1 OR 867032-17-5/B1 OR 867032-18-6/B1 OR 867032-19-7/B1 OR 867032-20-0/B1 OR 867032-21-1/B1 OR 867032-22-2/B1 OR 867032-23-3/B1 OR 867032-24-4/B1 OR 867032-25-5/B1 OR 867032-26-6/B1 OR 867032-27-7/B1 OR 867032-28-8/B1 OR 867032-29-9/B1 OR 867032-30-2/B1 OR 867032-31-3/B1 OR 867032-32-4/B1 OR 867032-33-5/B1 OR 867032-34-6/B1 OR 867032-35-7/B1 OR 867032-36-8/B1 OR 867032-37-9/B1 OR 867032-38-0/B1 OR 867032-39-1/B1
----	--

10/594,412

9/5/09

FILE 'HCAPLUS' ENTERED AT 13:36:48 ON 05 SEP 2009
L9 1 SEA ABB=ON L7 AND L8

FILE 'REGISTRY' ENTERED AT 13:37:54 ON 05 SEP 2009
L10 STR
L11 0 SEA SSS SAM L10
L12 20 SEA SSS FUL L10

FILE 'HCAPLUS' ENTERED AT 13:41:44 ON 05 SEP 2009
L13 1 SEA ABB=ON L12

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Sep 2009 VOL 151 ISS 11
FILE LAST UPDATED: 4 Sep 2009 (20090904/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/Cplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 SEP 2009 HIGHEST RN 1180743-67-2
DICTIONARY FILE UPDATES: 4 SEP 2009 HIGHEST RN 1180743-67-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>